RCS - Redx Pharma plc - Redx to Present Poster at ASN Kidney Week

Redx PharmaAnnouncement

27/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221027:nRSa2566Ea&default-theme=true

RNS Number : 2566E  Redx Pharma plc  27 October 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx to Present Poster on Preclinical Efficacy of a Novel, Selective Discoidin
Domain Receptor 1 Inhibitor at the American Society of Nephrology Kidney Week

 

Alderley Park, UK, 27 October 2022 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, today announces it will present a poster on its novel
preclinical Discoidin Domain Receptor 1 (DDR1) inhibitor programme at the
American Society of Nephrology (ASN) Kidney Week (3-6 November 2022, Orlando,
Florida).

 

As announced in January 2022, Redx is developing potent proprietary DDR
inhibitors with drug-like characteristics that are now in lead optimisation.
The poster will present compelling preclinical data on REDX12271, a novel,
potent, selective and orally active DDR1 inhibitor, in chronic kidney disease
models. DDRs are receptor tyrosine kinases containing a discoidin homology
domain in their extracellular region and which act as non-integrin collagen
receptors. There are two DDR receptors, DDR1 and DDR2, and DDR expression is
increased in many fibrotic diseases. DDRs have recently gained traction as new
druggable targets with the potential to treat multiple fibrotic conditions,
including kidney fibrosis. The poster supports the further investigation of
selective inhibition of DDR1 as a potential novel approach for the treatment
of renal fibrosis associated with chronic kidney disease.

 

 Title:                      REDX12271 is a novel, selective DDR1 inhibitor with the potential to treat
                             multiple chronic kidney diseases
 Poster Board:               TH-PO433

 Day/Date:                   Thursday, 3 November 2022
 Time:                       10:00-12:00
 Session name and category:   Posters Glomerular Diseases: Inflammation and Fibrosis  PO1301 

 

A copy of the poster will be made available on the Company's website
following the presentation
at: https://www.redxpharma.com/scientific-publications/
(https://www.redxpharma.com/scientific-publications/)

 

About Chronic Kidney Disease

Defined as a persistent abnormality in kidney structure or function (e.g.
glomerular filtration rate  GFR  <60 mL/min/1.73 m2 or albuminuria ≥30 mg
per 24 hours) for more than 3 months, chronic kidney disease (CKD) affects 8%
to 16% of the population worldwide. CKD is most commonly attributed to
diabetes and hypertension. However, less than 5% of patients with early CKD
report awareness of their disease. Among individuals diagnosed as having CKD,
staging and new risk assessment tools that incorporate GFR and albuminuria can
help guide treatment, monitoring, and referral strategies. While CKD is
progressive, optimal management can slow its progression to end-stage renal
disease (ESRD). This includes cardiovascular risk reduction (e.g., statins and
blood pressure management), treatment of albuminuria (e.g.
angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
and more recently SGLT2 inhibitors), avoidance of potential nephrotoxins (e.g.
nonsteroidal anti-inflammatory drugs). Renal fibrosis, characterized by
tubulointerstitial fibrosis and glomerulosclerosis, is one the final
manifestations of CKD as it progresses and is associated with high morbidity.
There are currently no approved treatments to address the interstitial
fibrotic component of this disease.(1)

 

 For further information, please contact:

 Redx Pharma Plc                                                      T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                          T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                       T: +44 (0)203 705 9330
 Claes SpŒng/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                           T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                       T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's lead fibrosis product candidate,
the selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis
in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in
pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor
targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF),
which AstraZeneca is progressing in a Phase 1 clinical study. In addition,
Redx has forged collaborations with Jazz Pharmaceuticals, which includes
JZP815, a preclinical pan-RAF inhibitor which has received IND clearance from
the US FDA, and an early stage oncology research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/

 

 

(1)Taken in part from Chen TK et al;  JAMA. 2019 Oct 1; 322(13): 1294Ð1304.
(https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=31573641)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADGBDGUUDDGDL